4/20
10:12 am
tsha
Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher [Yahoo! Finance]
Low
Report
Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher [Yahoo! Finance]
4/18
10:23 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
Low
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
4/11
08:06 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.00 price target on the stock.
Medium
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.00 price target on the stock.
4/9
08:09 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
Medium
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
4/5
08:00 am
tsha
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3/24
08:46 am
tsha
News Flash: Analysts Just Made A Notable Upgrade To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Forecasts [Yahoo! Finance]
Medium
Report
News Flash: Analysts Just Made A Notable Upgrade To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Forecasts [Yahoo! Finance]
3/21
11:43 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $7.00 price target on the stock.
Low
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $7.00 price target on the stock.
3/21
08:06 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target raised by analysts at Chardan Capital from $5.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target raised by analysts at Chardan Capital from $5.00 to $7.00. They now have a "buy" rating on the stock.
3/21
06:55 am
tsha
Taysha Gene Therapies Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Taysha Gene Therapies Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
3/20
12:39 pm
tsha
Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts [Seeking Alpha]
Medium
Report
Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts [Seeking Alpha]
3/20
10:36 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
Medium
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
3/20
09:05 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
Low
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
3/20
08:08 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target raised by analysts at Needham & Company LLC from $5.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target raised by analysts at Needham & Company LLC from $5.00 to $7.00. They now have a "buy" rating on the stock.
3/19
04:19 pm
tsha
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates [Yahoo! Finance]
Low
Report
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates [Yahoo! Finance]
3/19
04:01 pm
tsha
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
High
Report
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
3/14
04:41 pm
tsha
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 [Yahoo! Finance]
Medium
Report
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 [Yahoo! Finance]
3/14
04:26 pm
tsha
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
Medium
Report
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
3/4
07:43 am
tsha
4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer [Yahoo! Finance]
Medium
Report
4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer [Yahoo! Finance]
3/1
05:08 pm
tsha
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/29
03:42 pm
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Low
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
2/29
08:14 am
tsha
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome [Yahoo! Finance]
High
Report
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome [Yahoo! Finance]
2/29
08:00 am
tsha
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
High
Report
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
2/15
04:14 pm
tsha
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs [Yahoo! Finance]
High
Report
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs [Yahoo! Finance]
2/15
04:01 pm
tsha
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
High
Report
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
2/13
06:19 am
tsha
Owning 39% shares,institutional owners seem interested in Taysha Gene Therapies, Inc. (NASDAQ:TSHA), [Yahoo! Finance]
High
Report
Owning 39% shares,institutional owners seem interested in Taysha Gene Therapies, Inc. (NASDAQ:TSHA), [Yahoo! Finance]